European Archives - Page 1091 of 1117 - European Medical Journal

EMJ

Update: Diagnosis and Treatment of Muscle-Invasive and Metastatic Bladder Cancer in 2014

Bladder cancer (BC) is the ninth most commonly diagnosed malignant tumour in the world, with an incidence of about 356,000 and a mortality of about 145,000 per year in both non-muscle-invasive and muscle-invasive BC.

Percutaneous Nephrolithotomy in Children

Although urolithiasis is considered as a rare entity in children, it is an important health problem in the world, especially in endemic areas.

Biosimilars in Hematology: Increasing Choice, Expanding Access

Biologicals have revolutionised modern medicine by offering vital therapeutic options to treat or prevent complex, disabling, and life-threatening diseases.

Next Steps in Front-Line Treatment of Lymphoma: The Road Ahead

Prof Zelenetz opened the symposium on the evolving front-line treatment options for follicular lymphoma (FL) and discussed the potential of novel agents…

The Multiple Facets of Thrombotic Microangiopathies

The Alexion satellite symposium was introduced by Prof Pier Mannuccio Mannucci who provided an introduction to the history of thrombotic…

The Standard of Care in Relapsed Refractory CD30+ Lymphoma

CD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances…

Overcoming Immunodeficiency in Chronic Lymphocytic Leukaemia: Current Knowledge and Perspectives

While the standard of care for chronic lymphocytic leukaemia (CLL) leads to high overall response rates and a long progression-free survival, it can be…

The Role of CD49d in Chronic Lymphocytic Leukaemia: Microenvironmental Interactions and Clinical Relevance

Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease characterised by the accumulation/expansion of a clonal population of…

Current Developments and Perspectives in Multiple Myeloma

In the last decades, advances in the therapeutic management of multiple myeloma (MM) with new drug armamentarium and strategies have significantly…

Autologous Stem Cell Transplantation In Multiple Myeloma: Is It Still The Right Choice?

Autologous stem cell transplantation (ASCT) is considered the standard of care for multiple myeloma patients aged <65 years with no relevant…